289 related articles for article (PubMed ID: 33294085)
1. Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases.
Wu JN; Chen JR; Chen JL
Can Respir J; 2020; 2020():9137251. PubMed ID: 33294085
[TBL] [Abstract][Full Text] [Related]
2. Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways.
Chen B; Cai HR; Xue S; You WJ; Liu B; Jiang HD
Respirology; 2016 Aug; 21(6):1075-80. PubMed ID: 27185272
[TBL] [Abstract][Full Text] [Related]
3. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
4. The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases.
Kim DH; Park JS; Choi HI; Kim CS; Bae EH; Ma SK; Kim SW
Exp Mol Med; 2023 Feb; 55(2):304-312. PubMed ID: 36737665
[TBL] [Abstract][Full Text] [Related]
5. Targeting Farnesoid X Receptor in Tumor and the Tumor Microenvironment: Implication for Therapy.
Nenkov M; Shi Y; Ma Y; Gaßler N; Chen Y
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203175
[TBL] [Abstract][Full Text] [Related]
6. FXR signaling in the enterohepatic system.
Matsubara T; Li F; Gonzalez FJ
Mol Cell Endocrinol; 2013 Apr; 368(1-2):17-29. PubMed ID: 22609541
[TBL] [Abstract][Full Text] [Related]
7. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
8. Progress and challenges of selective Farnesoid X Receptor modulation.
Massafra V; Pellicciari R; Gioiello A; van Mil SWC
Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
[TBL] [Abstract][Full Text] [Related]
9. microRNA-192 suppresses the expression of the farnesoid X receptor.
Krattinger R; Boström A; Schiöth HB; Thasler WE; Mwinyi J; Kullak-Ublick GA
Am J Physiol Gastrointest Liver Physiol; 2016 Jun; 310(11):G1044-51. PubMed ID: 27079614
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1.
You W; Chen B; Liu X; Xue S; Qin H; Jiang H
Sci Rep; 2017 Apr; 7(1):591. PubMed ID: 28377627
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of the intestinal nuclear bile acid farnesoid X receptor (FXR) by the caudal-related homeobox 2 (CDX2).
Modica S; Cariello M; Morgano A; Gross I; Vegliante MC; Murzilli S; Salvatore L; Freund JN; Sabbà C; Moschetta A
J Biol Chem; 2014 Oct; 289(41):28421-32. PubMed ID: 25138215
[TBL] [Abstract][Full Text] [Related]
12. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of farnesoid X receptor in small airways contributes to epithelial to mesenchymal transition and COX-2 expression in chronic obstructive pulmonary disease.
Chen B; You WJ; Xue S; Qin H; Zhao XJ; Zhang M; Liu XQ; Zhu SY; Jiang HD
J Thorac Dis; 2016 Nov; 8(11):3063-3074. PubMed ID: 28066584
[TBL] [Abstract][Full Text] [Related]
14. Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice.
Massafra V; Milona A; Vos HR; Ramos RJJ; Gerrits J; Willemsen ECL; Ramos Pittol JM; Ijssennagger N; Houweling M; Prinsen HCMT; Verhoeven-Duif NM; Burgering BMT; van Mil SWC
Gastroenterology; 2017 May; 152(6):1462-1476.e10. PubMed ID: 28130067
[TBL] [Abstract][Full Text] [Related]
15. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
16. Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease.
van Zutphen T; Bertolini A; de Vries HD; Bloks VW; de Boer JF; Jonker JW; Kuipers F
Handb Exp Pharmacol; 2019; 256():207-234. PubMed ID: 31236687
[TBL] [Abstract][Full Text] [Related]
17. Bile acid nuclear receptor FXR and digestive system diseases.
Ding L; Yang L; Wang Z; Huang W
Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
[TBL] [Abstract][Full Text] [Related]
18. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
[TBL] [Abstract][Full Text] [Related]
19. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
20. Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma.
Chen Y; Song X; Valanejad L; Vasilenko A; More V; Qiu X; Chen W; Lai Y; Slitt A; Stoner M; Yan B; Deng R
Hepatology; 2013 Apr; 57(4):1530-41. PubMed ID: 23213087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
